IL-15 receptor alpha deficiency triggers depressive-like behaviors via enhanced microglial synapse pruning

Yue Tang1,2, Yu Huang1,2, Jing Pan1,2

  • 1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Molecular Psychiatry
|April 22, 2026
PubMed

Insights

Interleukin-15 receptor alpha (IL-15RA) deficiency in mice triggers neuroinflammation and synaptic changes, contributing to depression. Targeting the CX3CL1/CX3CR1 pathway reversed these effects, offering a potential therapeutic strategy for Major Depressive Disorder (MDD).

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Major Depressive Disorder (MDD) is linked to neuroinflammation, but underlying mechanisms are unclear.
  • Interleukin-15 receptor subunit alpha (IL-15RA) role in MDD pathogenesis requires further investigation.

Purpose of the Study:

  • To investigate the impact of IL-15RA deficiency on brain transcriptomics and behavior in mice.
  • To elucidate the cellular and molecular mechanisms of IL-15RA deficiency in depression-like behaviors.

Main Methods:

  • Single-nucleus RNA sequencing of the prefrontal cortex in IL-15RA knockout mice.
  • Co-expression network analysis to identify gene clusters and pathways.
  • Morphological analysis of microglia and synapses.
  • Pharmacological inhibition of the CX3CL1/CX3CR1 signaling pathway.

Main Results:

  • IL-15RA deficiency caused cell-type-specific transcriptomic alterations, impacting synapse assembly.
  • Dysregulated neuron-microglial interactions were identified, involving the CX3CL1/CX3CR1 pathway.
  • Microglial activation and excessive synapse pruning were observed in IL-15RA knockout mice.
  • Inhibition of CX3CL1/CX3CR1 signaling reversed depression-like behaviors and synaptic abnormalities.

Conclusions:

  • IL-15RA deficiency contributes to MDD onset by altering microglia-mediated synaptic remodeling.
  • The CX3CL1/CX3CR1 signaling pathway is a critical mediator of these effects.
  • Targeting this neuroimmune pathway presents a potential therapeutic strategy for MDD.